Document Detail


Patient profiles in psoriatic disease: a case-based approach.
MedLine Citation:
PMID:  18341241     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Psoriasis and psoriatic arthritis are related conditions that can have numerous untoward consequences. Moreover, appropriate management of these conditions can be challenging, as each affected patient has unique needs that must be addressed. With that in mind, the authors discuss three real-life cases, highlighting principles that may facilitate the effective case-by-case management of psoriatic disease.
Authors:
Mary Wiatrowski; Nicole Furfaro
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Dermatology nursing / Dermatology Nurses' Association     Volume:  Suppl     ISSN:  1060-3441     ISO Abbreviation:  Dermatol Nurs     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2008-03-17     Completed Date:  2008-04-29     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9011113     Medline TA:  Dermatol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5-19; quiz 20-1     Citation Subset:  N    
Affiliation:
Texas Dermatology Associates' Specialty Psoriasis Clinic, Dallas, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / diagnosis,  drug therapy*
Female
Humans
Immunoglobulin G / therapeutic use
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Receptors, Tumor Necrosis Factor / antagonists & inhibitors*,  therapeutic use
Recombinant Fusion Proteins / therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Receptors, Tumor Necrosis Factor; 0/Recombinant Fusion Proteins; 0/efalizumab; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; ELK3V90G6C/alefacept; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Empire matters: implications for pastoral care.
Next Document:  Quantitative structure-activity relationship study of ATP-sensitive potassium channel openers: deriv...